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Over the last 20 years, the incidence of melanoma has been rising
rapidly in white populations in the USA and other parts of the
world (Liu and Soong, 1996). Sun exposure, particularly when
intermittent (Holman et al, 1986; Osterlind et al, 1988a) or when
resulting in burns or blisters (Osterlind et al, 1988a; MacKie et al,
1989), is a strong risk factor for melanoma, and recent changes in
lifestyle that embrace exposure to sunlight may partially account
for this rise in incidence.
Oestrogens, either alone or in combination with progesterone,
increase the number of melanocytes and their melanin content
(Snell and Bischitz, 1960) and can cause hyperpigmentation of the
skin (Jelinek, 1970) and thus have been implicated as another
possible risk factor in the development of melanoma. Among
women, incidence rates rise steeply until about age 50, after which
the rate of increase slows (Armstrong and English, 1996), further
suggesting a role for oestrogen.
Interest in oral contraceptive use was simulated by two early
studies from the same cohort in California which reported elevated
risk of melanoma among ever versus never users (Beral et al,
1977; Ramcharan et al, 1981). However, subsequent research has
not generally supported this finding (Helmrich et al, 1984; Holman
et al, 1984; Gallagher et al, 1985; Osterlind et al, 1988b; Zanetti et
al, 1990; Hannaford et al, 1991; Palmer et al, 1992; Holly et al,
1995; Westerdahl et al, 1996). Failure to find an association
between melanoma and oral contraceptive use may be due to the
broad categorization of ‘ever users’. A few studies have reported
modest elevations in melanoma risk among women with longer
durations of use or with longer times since first use (Bain et al,
1982; Holly et al, 1983; Beral et al, 1984; Le et al, 1992).
However, previous research has been limited by the predominance
of case–control designs that rely on recall of oral contraceptive
use. In this investigation, we examined prospectively the risk of
melanoma by status, duration, and other measures of oral contra-
ceptive use among premenopausal women in two large cohorts:
the Nurses’ Health Study (NHS) and the Nurses’ Health Study II
(NHS II).
METHODS
The NHS (Colditz et al, 1997) is an ongoing cohort study that was
begun in 1976 with 121 700 married female nurses 30–55 years of
age and residing in 1 of 11 States across the USA. A second
cohort, NHS II, was created in 1989 with 116 671 married and
unmarried female nurses 25–42 years of age and residing in 1 of
14 States. Both studies were designed to examine prospectively
the effects of oral contraceptive use and other lifestyle factors on
chronic diseases, particularly cancers and cardiovascular diseases.
Information is collected with biennial mailed questionnaires, and a
response rate of at least 90% has been achieved in each follow-up
cycle. Deaths are ascertained through the National Death Index.
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Oral contraceptive use
On the baseline questionnaires for both cohorts, participants were
asked whether they had ever used oral contraceptives (OC), and if
so, to list all periods of use. Subsequent biennial questionnaires
asked whether OCs had been used during the previous 2 years and,
if so, the number of months of use. From the responses to these
questions, a status of OC use (never, past, current) was assigned.
We also calculated duration of use, age at first use, and time since
first use for past and current users and time since last use for past
users. These measures characterized participants in the subsequent
2-year follow-up cycle.
In NHS II, participants identified the exact preparation of their
OC pill with the aid of a booklet containing photos of all OCs ever
marketed in the USA. From this information, we were able to
determine oestrogen dosages. The reproducibility and validity of
the OC data were evaluated in a study among 215 randomly
selected participants from NHS II (Hunter et al, 1997). The
biennial questionnaire responses were compared with data from a
subsequent telephone interview that used a structured life events
calendar to assist recall of past OC use. Agreement for ever versus
never use was 99%, and the correlation for duration of use calcu-
lated from the two sources was 0.94. Medical records confirmed
the identical or equivalent OC brand in 75% of the reports for
which data were obtained.
Covariate information
In both cohorts, age, parity, and body weight were reassessed at
each 2-year follow-up cycle. Height was reported only at baseline.
In NHS, skin reaction after 2 or more hours in the sun during
childhood, number of sunburns over the lifetime, natural hair colour
at age 21, and family history (parental or sibling) of melanoma were
reported in 1982 and number of moles on the left arm was reported
in 1986. These measures were used to characterize follow-up from
baseline in 1976. Family history was reassessed in 1992.
In NHS II, skin reaction after 2 or more hours in the sun during
childhood, number of sunburns between ages 15 and 20, number
of moles on the lower legs, and family history (parental or sibling)
of melanoma were reported at baseline. Natural hair colour at age
21 was reported in 1991 and was used to characterize follow-up
from baseline in 1989.
Study population and case confirmation
Only caucasian women who were premenopausal and had no
history of cancer (except non-melanoma skin cancer) were
included in the study populations. Participants were followed from
the return date of their baseline questionnaire (mailed June 1976
for NHS and September 1989 for NHS II) until a report of
melanoma, other cancer, menopause, death, or end of follow-up (1
June 1994 for NHS and 1 June 1995 for NHS II), whichever
occurred first. The NHS study population included 79 571 women
and 740 182 person-years of follow-up; NHS II included 104 122
women and 538 807 person-years of follow-up.
Among these women, 260 reported a diagnosis of melanoma on
the NHS questionnaires from 1976 to 1994 and 216 reported a
diagnosis of melanoma on the NHS II questionnaires from 1989 to
1995. Medical records were obtained for 217 (83%) of the NHS
Table 1 Age and age-standardized characteristics of premenopausal Caucasian women in the Nurses’ Health Study (NHS) and Nurses’ Health Study II
(NHS II) cohorts by status of oral contraceptive (OC) use and by duration of use among past and current users
Status of OC use Duration of OC use (years)
Never Past Current <5 5–9.9 10+
NHSa
Person-years (thousands) 275.2 444.7 20.3 307.5 109.3 36.7
Age (years, mean) 44.4 42.4 38.2 41.9 42.3 44.3
Height (metres, mean) 1.64 1.64 1.64 1.64 1.64 1.64
Body mass index (kg m–2, mean) 24.6 24.3 23.4 23.9 24.1 23.9
Painful burn or blisters after 2 h 14 15 13 15 13 14
of sun exposure during childhood (%)
10+ sunburns over lifetime (%) 37 41 38 41 41 40
3+ moles on left arm (%) 9 10 9 11 11 9
Red or blonde hair (%) 14 15 16 15 15 16
Parent of sibling with melanoma (%) 3 3 2 3 2 2
Nulliparous (%) 7 5 5 5 4 7
NHS IIa
Person-years (thousands) 82.7 394.9 61.2 270.0 130.9 50.3
Age (years, mean) 35.7 36.7 32.2 36.2 35.6 36.3
Height (metres, mean) 1.65 1.65 1.65 1.65 1.65 1.65
Body mass index (kg m–2, mean) 24.6 24.0 23.2 24.0 23.8 23.7
Painful burn or blisters after 2 h 10 18 18 18 18 17
of sun exposure during childhood (%)
3+ sunburns during teen years (%) 25 28 27 27 29 28
5+ moles on lower legs (%) 20 22 22 22 22 22
Red or blonde hair (%) 18 21 22 20 22 23
Parent or sibling with melanoma (%) 4 4 4 4 4 4
Nulliparous (%) 35 22 39 22 24 39
aThe NHS cohort included 79 571 women who were followed from 1976 until 1994; the NHS II cohort included 104 122 women who were followed from 1989
until 1995.920 D Feskanich et al
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reports and for 156 (72%) of the NHS II reports. Obtainment of
medical records did not differ by status of OC use. Among the
medical records, 146 (67%) in NHS and 106 (68%) in NHS II were
confirmed cases of invasive melanoma. These included superficial
spreading (20%), nodular (76%) and unspecified (4%) types.
Women who reported a diagnosis of melanoma that was not
confirmed by medical record (in situ cancer or other skin condi-
tions) or for whom we could not obtain a medical record were
excluded from further follow-up.
Statistical analyses
The NHS and NHS II cohorts were analysed separately. Incidence
rates were estimated for never, past and current OC users within 5-
year age groups by dividing the number of melanoma cases by the
person-time of follow-up in each of the OC status/age group cate-
gories, and relative risks for past and current users were estimated
by their incidence rates divided by the rate for never users. For
each of the cohorts, pooled logistic regression models within 2-
year time increments were used to calculate multivariate relative
risks adjusted for all covariates simultaneously (D’Agostino et al,
1990). Age-adjusted and multivariate relative risks were similarly
calculated for duration of OC use, age at first use, time since first
use and time since last use, using never OC use as the reference
category. Tests for trend were performed by entering continuous
variables into the multivariate logistic regression models, using the
median value within each category. Trend tests did not include the
reference category of never users.
Analyses of OC status were stratified by a risk score determined
by factors which were associated with significant increases in risk
of melanoma, including hair colour, sunburn history and mole
count. In NHS II, analyses were also stratified by oestrogen dosage
in the OC preparation.
To increase the precision of the risk estimates and obtain a
single summary of the results from NHS and NHS II, a random
effects model (Dersimonian and Laird, 1986) was used to combine
the risk estimates. Data were combined only when there was no
significant evidence of heterogeneity between results from the
separate cohorts.
RESULTS
The following factors were associated with a significant increased
risk of melanoma: red or blond hair colour, having a parent or
sibling with melanoma, ten or more sunburns over the lifetime
(NHS) or three or more during the teenage years (NHS II), three or
more moles on the left arm (NHS) or five or more on the lower
legs (NHS II), painful burning or blistering after 2 or more hours
of sun exposure during childhood (NHS), nulliparity (NHS II) and
a height of 1.68 metres or more (NHS). However, except for parity
and skin reaction to sun exposure during childhood, these
melanoma risk factors were not related to status or duration of OC
use (Table 1). In NHS II, nulliparous women were more likely to
be a current than a past OC user and they were more likely to have
used OCs for 10 or more years than for shorter periods. Also in this
cohort, painful burning or blistering after 2 or more hours of sun
exposure during childhood was least likely among the never OC
users. In both cohorts, current OC users were younger than never
or past users.
In NHS, the multivariate-adjusted relative risk (RR) of
melanoma among current OC users was significantly elevated
(RR = 2.6, 95% confidence interval (CI) 1.2–5.6) compared to
women who never used OCs (Table 2). Statistical adjustment for
all measured covariates in the multivariate model did not notably
alter the risk estimate from that produced by the simple age-
adjusted model. Current OC users in NHS II also experienced an
increased risk of melanoma compared to never users (RR = 1.6,
95% CI 0.8–3.3), though the magnitude was not as great as that
observed in NHS (P-value test for heterogeneity = 0.4). When
results from NHS and NHS II were combined, current OC use was
Table 2 Cohort-specific and combined relative risks of invasive melanoma by status and duration of oral contraceptive (OC) use among premenopausal
Caucasian women in the Nurses’ Health Study (NHS) and the Nurses’ Health Study II (NHS II). Never OC use is the reference group for all categories
NHS NHS II
Combined
Person- RR1 RR2 Person- RR1 RR2 RR2
Cases years (95% CIa) (95% CIa) Cases years (95% CIa) (95% CIa) (95% CIa)
Never OC use 50 275 217 1.0 1.0 14 82 657 1.0 1.0 1.0
Past OC use 88 444 700 1.1 1.1 77 394 944 1.1 1.1 1.1
(0.8–1.6) (0.7–1.5) (0.6–2.0) (0.6–2.0) (0.8–1.5)
< 5 years 57 302 731 1.1 1.0 41 251 029 0.9 0.9 1.0
(0.7–1.6) (0.7–1.5) (0.5–1.7) (0.5–1.7) (0.7–1.4)
5–9.9 years 23 100 561 1.3 1.2 24 107 265 1.3 1.3 1.2
(0.8–2.1) (0.7–2.1) (0.7–2.5) (0.6–2.5) (0.8–1.9)
10+ years 7 30 204 1.3 1.2 11 32 742 1.8b 1.7b 1.4b
(0.6–2.8) (0.6–2.7) (0.8–4.1) (0.8–3.7) (0.8–2.5)
Current OC use 8 20 265 2.6 2.6 15 61 205 1.7 1.6 2.0
(1.2–5.7) (1.2–5.6) (0.8–3.6) (0.8–3.3) (1.2–3.4)
<10 years 2 13 490 0.9 0.9 7 42 636 1.3 1.2 1.0
(0.2–4.0) (0.2–3.8) (0.5–3.2) (0.5–3.0) (0.4–2.8)
10+ years 6 6 563 5.3 5.2 8 17 581 2.7 2.4 3.4
(2.3–12) (2.2–12) (1.1–6.5) (1.0–5.7) (1.7–7.0)
RR1 = relative risk adjusted for age; RR2 = relative risk adjusted for age, follow-up cycle, skin reaction after 2 hours of sun exposure during childhood, number
of sunburns over lifetime (NHS) or during teenage years (NHS II), number of moles on left arm (NHS) or on lower legs (NHS II), hair colour, family history of
melanoma, parity, height, and body mass index. a95% confidence interval; bP ≤ 0.05 in test for linear trend over categories of OC use (not including never
OC use).Oral contraceptives and melanoma 921
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associated with a significant twofold increase in risk (RR = 2.0,
95% CI 1.2–3.4). In both cohorts, there was little increase in risk
among past OC users compared to never users. A comparison of
ever versus never OC use yielded a combined multivariate-
adjusted RR of 1.4 (95% CI 0.8–1.6).
We identified women at high risk of melanoma as those with red
or blonde hair colour, a history of sunburns (ten or more over the
lifetime in NHS, three or more during teenage years in NHS II), or
a substantial number of moles (three or more on the left arm in
NHS, five or more on the lower legs in NHS II). Women in the high
risk category in NHS and NHS II had a combined RR of 2.4 (95%
CI 1.7–3.3) compared to those in the low risk category (i.e. all those
not at high risk). We then reassessed the association between OC
use and melanoma in analyses stratified by high versus low risk.
Among the high-risk women, current OC use was associated with a
significantly elevated risk of melanoma (combined RR = 3.1, 95%
CI 1.6–5.9), while there was no increase in risk among the low-risk
women (combined RR = 1.0, 95% CI 0.2–3.9). However, a test for
interaction was not significant (P = 0.7).
Analyses of duration of OC use were performed separately for
past and current users (Table 2). Compared to never OC users,
women in the NHS and NHS II with 10 or more years of current
OC use had a combined multivariate-adjusted RR of 3.4 (95% CI
1.7–7.0). The risk estimate was higher in NHS than in NHS II.
Though data were sparse for current OC users with shorter dura-
tions, there was no indication that risk was increased with fewer
than 10 years of use. Among past OC users, 10 or more years of
use was not associated with significant increases in risk of
melanoma (combined multivariate-adjusted RR = 1.4, 95% CI
0.8–2.5). However, the risk was higher in NHS II (RR = 1.7, 95%
CI 0.8–3.7) than in NHS, and there was a significant trend over
duration categories among past users.
We speculated that the risk of melanoma associated with current
OC use was higher in NHS than in NHS II due to the higher
oestrogen dosages that were popular during the earlier years of OC
use among the NHS cohort. Unfortunately, we had no data on
oestrogen dosage in the NHS cohort. Therefore, we examined risk
of melanoma by duration of use of low- (< 35 mg), medium-
(35–49 mg) and high- (50+ mg) dose oestrogen pills in the NHS II
cohort. Though power was limited, a higher oestrogen dose did not
appear to be associated with a higher risk of melanoma. Compared
to women who never used the low-dose oestrogen pills, the multi-
variate-adjusted RR of melanoma among women with 5 or more
years of low dose use was 1.4 (95% CI 0.6–3.2). This analysis was
adjusted for years of medium-dose and high-dose oestrogen use.
Similarly, the multivariate RR of melanoma among women with
5 or more years of high-dose oestrogen use compared to those
who never used the high-dose oestrogen pills was 1.6 (95%
CI 0.9–3.3).
With a twofold increase in risk of melanoma among current OC
users, and little increase in risk among past users, we anticipated
that risk would be elevated among past users who recently stopped
using OCs and that risk would decline with longer times since last
use. However, our data did not support this expectation. After
controlling for all covariates plus duration of OC use, the
combined RR for fewer than 5 years since last OC use was 1.2
(95% CI 0.7–2.0). Risk was not increased even among past users
with fewer than 2 years since last use (combined RR = 0.8, 95% CI
0.4–1.8). The median time since last use was 10 years in NHS and
11 years in NHS II.
We tested the hypothesis that risk of melanoma is increased with
earlier exposure to OCs by examining time since first use and age
at first use. Though the age-adjusted results were suggestive of an
increased risk with earlier OC exposure, the multivariate-adjusted
analyses did not support this hypothesis. Combined results from
NHS and NHS II yielded an RR of 1.2 (95% CI 0.7–1.9) among
women with 20 or more years since first OC use and an RR of 1.2
(95% CI 0.7–2.2) among women who began OC use before 20
years of age compared to women who never used OCs (Table 3).
To determine whether risk might be greater with an even earlier
age at first use, we examined women who began OC use before
age 18 in the NHS II cohort (there were few women and no cases
within this category in NHS). However, risk was not elevated in
this lower age-at-first-use category (RR = 1.0, 95% CI 0.5–2.3).
Table 3 Relative risks of invasive melanoma by measures of first and last oral contraceptive (OC) use among premenopausal Caucasian women in the
Nurses’ Health Study (NHS) and the Nurses’ Health Study II (NHS II). Never OC use is the reference group for all categories
Combined NHS and NHS II
Cases Person-years RR1 (95% CIa)R R 2 (95% CIa)
Never OC use 64 357,874 1.0 1.0
Time since last OC use
< 5 years 41 169,614 1.5 (1.0–2.3) 1.2 (0.7–2.0)
5–9.9 years 29 201,838 0.9 (0.6–1.4) 0.8 (0.5–1.3)
10–14.9 years 41 217,598 1.0 (0.6–1.6) 1.0 (0.7–1.6)
15+ years 49 214,371 1.3 (0.7–2.2) 1.5 (0.9–2.5)
Time since first OC use
< 10 years 14 135,409 0.8 (0.4–1.4) 0.7 (0.4–1.4)
10–19.9 years 118 531,747 1.2 (0.9–1.7) 1.1 (0.8–1.5)
20+ years 54 226,442 1.4 (0.9–2.3) 1.2 (0.7–1.9)
Age at first OC use
< 20 years 44 192,129 1.5 (0.8–2.6) 1.2 (0.7–2.2)
20–24 years 86 403,115 1.4 (0.9–2.0) 1.2 (0.8–1.8)
25+ years 56 295,939 1.1b (0.7–1.5) 1.0 (0.7–1.4)
RR1 = relative risk adjusted for age; RR2 = relative risk adjusted for age, follow-up cycle, skin reaction after 2 hours of sun exposure during childhood, number of
sunburns over lifetime (NHS) or during teenage years (NHS II), number of moles on left arm (NHS) or on lower legs (NHS II), hair colour, family history of
melanoma, parity, height, body mass index, and duration of OC use. a95% confidence interval; bP ≤ 0.05 in test for linear trend over categories of OC use (not
including never OC use).922 D Feskanich et al
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DISCUSSION
In this prospective study among premenopausal caucasian women,
current OC use was associated with a significant twofold increase
in risk of melanoma. The risk appeared stronger in the NHS cohort
than in the NHS II cohort. This could be due to the higher dosages
of oestrogen in the OC pills that were available during the early
years of the NHS study. Lack of data on the composition of the
pills taken by NHS participants prevented us from examining this
hypothesis in this cohort. In NHS II, there was no evidence that
higher estrogen dosages conferred additional risk, though power
to assess this association was limited. We found no appreciable
overall excess risk of melanoma among past OC users, suggesting
that the effects diminish rapidly after OC use is terminated. Even
among the past users with fewer than 2 years since last OC use,
there was no evidence of an increase in risk of melanoma. An
increase in risk among current OC users and a quickly diminishing
risk after quitting is similar to the pattern observed for OC use and
breast cancer (Collaborative Group on Hormonal Factors in Breast
Cancer) and is consistent with a model of tumour promotion rather
than tumour initiation.
The lack of association between ever use of OCs and risk of
melanoma in previous studies may be due to a preponderance of
past versus current users in the study populations, most of which
included women in their post-menopausal years. Few studies
examined current OC users separately. Palmer et al (1992)
reported a non-significant relative risk of 1.5 for current OC use
for cases of non-severe melanoma, and Bain et al (1982) found an
increase in risk of similar magnitude among women under 40
years of age, a period when OC use is more common.
In both the NHS and NHS II, only current OC users experienced
a significant increased risk of melanoma with longer durations of
use. Compared to never OC users, durations of 10 or more years of
use were associated with an over threefold increase in risk. Failure
of some previous studies to observe an increased risk of melanoma
with longer durations of OC use may be attributed to a combined
analysis of past and current users and a definition of high duration
that included women with only 3 or 5 years of OC use (Holman et
al, 1984; Gallagher et al, 1985; Zanetti et al, 1990). Among those
studies which examined women with 10 or more years of past or
current OC use, four reported relative risks comparable to our find-
ings (Holly et al, 1983; Beral et al, 1984; Hannaford et al, 1991; Le
et al, 1992), while others found no increase in risk of melanoma
(Helmrich et al, 1984; Holly et al, 1995; Osterlind et al, 1988b).
However, Holly et al (1995) did report a statistically significant
relative risk of 1.7 among women with 5 or more years of OC use
and fewer than 15 years since first use, a group which likely
included many current OC users.
Some have suggested that OCs may have a stronger effect when
used earlier in life and that a long latency period may be required
before the appearance of melanoma. Le et al (1992) found that past
OC users with 15 or more years since first use had a twofold risk
for melanoma compared to never users, while no increase in risk
was found among women with shorter latency periods. The rela-
tive risk increased to threefold among those who also used OCs for
10 or more years. Holly et al (1983) and Beral et al (1984) also
found that risk of melanoma was highest among those with both
long durations and latency periods. Our data did not support these
findings. Risk of melanoma was not significantly elevated among
women who began OC use before the age of 20 or for whom 20 or
more years had passed since their first use. Other studies have also
reported no association between melanoma and time since first OC
use or age at first use (Palmer et al, 1992; Holly et al, 1995). There
may be an interaction between duration of use and time since first
use, as suggested by earlier studies, but we did not have the power
to examine this in our data.
It is biologically plausible that oestrogen may have an effect on
the development of melanoma. In animal experiments, oestrogen
and oestrogen–progesterone combinations stimulate melano-
genesis and cause an increase in both intracellular and extracel-
lular melanin content (Snell and Bischitz, 1960). This is thought to
be the underlying reason for the hyperpigmentation associated
with OC use (Jelinek, 1970). Hyperpigmentation is most
commonly caused by sun exposure which is a strong risk factor for
melanoma, particularly with exposures during childhood or early
adulthood that result in burns or blisters (Weinstock et al, 1989).
Oestrogen receptors have been found in human melanoma tissue
(Fisher et al, 1976; Chaudhuri et al, 1980) but their biological
significance is uncertain. Though high-affinity binding has been
observed, specificity may be poor (McCarty et al, 1980). Initial
case reports suggested that tamoxifen could produce tumour regres-
sion in patients with metastatic melanoma (Nesbit et al, 1979;
Mirimanoff et al, 1981). However, in larger trials, response rates
were low (Telhaug et al, 1982; Wagstaff et al, 1982). More recent
clinical investigations indicate that the addition of tamoxifen can
increase the response rate to chemotherapy (Cocconi et al, 1992;
McClay et al, 1992), though the mechanism may not involve an
anti-oestrogenic effect on oestrogen receptors (McClay et al, 1993).
We speculated that OC use by itself may not increase the risk of
melanoma but may promote carcinogenesis in women with other
significant risk factors. In the NHS and NHS II cohorts, risk for
current OC use was threefold among the women defined as high
risk and was null among those at low risk, though a test for hetero-
geneity was not significant. This issue merits examination in other
studies.
Our study of OC use and melanoma is one of the few prospec-
tive investigations on this topic. Another major advantage of this
study was the availability of data on other reproductive and non-
reproductive risk factors for melanoma which permitted us to
control for possible confounding effects. Though we did have a
sunburn history and a measure of susceptibility to sunburn, the
study was limited by lack of information on sunbathing habits and
the use of sunscreen or other protective measures during periods of
OC use. This could confound our results if women who use OCs
have higher levels of sun exposure. There is also the possibility
that detection bias could explain at least part of the increased risk
of melanoma observed among current OC users if they are more
likely to get diagnosed due to more frequent physician visits.
However, in our cohorts, the percent of women with annual
physical exams was high and did not differ by OC use.
In conclusion, current use of oral contraceptives was associated
with an increased risk of melanoma in premenopausal Caucasian
women, particularly among current users with 10 or more years of
use. Since this study began in 1976 when higher oestrogen dose
pills were commonly used, further research is needed to determine
whether the current lower dose pills are also associated with an
increase in melanoma risk.
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